Alpharma to Pay $42.5M to Resolve Kickback, False Claims Act Allegations
Alpharma Inc. will pay $42.5 million to resolve whistleblower kickback and False Claims Act allegations for its marketing of the painkiller Kadian, the Justice Department said.
Federal prosecutors alleged that between 2000-2008 Alpharma paid healthcare providers to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the morphine-based drug.
Alpharma was sold to Bristol, TN-based King Pharmaceuticals Inc. in November 2008. Calls Tuesday night to King Pharmaceuticals were not immediately returned.
The settlement resolves a lawsuit brought by whistleblower Debra Parks in 2006. Parks will receive $5.33 million out of the federal government's $33.6 million share of the recovery, and several states will share approximately $8.9 million.
"Healthcare decisions must be based solely upon what is best for the individual patient and not on which pharmaceutical company is paying the doctor the biggest kickback," said Rod J. Rosenstein, the US Attorney in Maryland, in a media release.
The Justice Department's total recoveries in False Claims Act cases since January 2009 have topped $3 billion, according to the department.
John Commins is a senior editor with HealthLeaders Media.
- EHR Systems 'Immature, Costly,' AMA Says
- Better HCAHPS Scores Protect Revenue
- Narrow Networks Cut Costs, Not Quality, Economists Say
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- Interstate Medical Licensure Effort Advances
- CEO Exchange: Preparing for Population Health
- 'Early Offer' Malpractice Programs May Spur Reform
- How to Build a Health Plan from Scratch
- Data Points to Boom in Private HIX
- 3 Strategies for Retaining Millennial Employees